Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2004 May 1;379(Pt 3):731–738. doi: 10.1042/BJ20031456

Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR).

Cor A Berrevoets 1, Arzu Umar 1, Jan Trapman 1, Albert O Brinkmann 1
PMCID: PMC1224119  PMID: 14744261

Abstract

Antiandrogens are widely used agents in the treatment of prostate cancer, as inhibitors of AR (androgen receptor) action. Although the precise mechanism of antiandrogen action is not yet elucidated, recent studies indicate the involvement of nuclear receptor co-repressors. In the present study, the regulation of AR transcriptional activity by N-CoR (nuclear receptor co-repressor), in the presence of different ligands, has been investigated. Increasing levels of N-CoR differentially affected the transcriptional activity of AR occupied with either agonistic or antagonistic ligands. Small amounts of co-transfected N-CoR repressed CPA (cyproterone acetate)- and mifepristone (RU486)-mediated AR activity, but did not affect agonist (R1881)-induced AR activity. Larger amounts of co-transfected N-CoR repressed AR activity for all ligands, and converted the partial agonists CPA and RU486 into strong AR antagonists. In the presence of the agonist R1881, co-expression of the p160 co-activator TIF2 (transcriptional intermediary factor 2) relieved N-CoR repression up to control levels. However, in the presence of RU486 and CPA, TIF2 did not functionally compete with N-CoR, suggesting that antagonist-bound AR has a preference for N-CoR. The AR mutation T877A (Thr877-->Ala), which is frequently found in prostate cancer and affects the ligand-induced conformational change of the AR, considerably reduced the repressive action of N-CoR. The agonistic activities of CPA- and hydroxyflutamide-occupied T877A-AR were hardly affected by N-CoR, whereas TIF2 strongly enhanced their activities. These results indicate that lack of N-CoR action allows these antiandrogens to act as strong agonists on the mutant AR.

Full Text

The Full Text of this article is available as a PDF (219.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alland L., Muhle R., Hou H., Jr, Potes J., Chin L., Schreiber-Agus N., DePinho R. A. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature. 1997 May 1;387(6628):49–55. doi: 10.1038/387049a0. [DOI] [PubMed] [Google Scholar]
  2. Balk Steven P. Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132–139. doi: 10.1016/s0090-4295(02)01593-5. [DOI] [PubMed] [Google Scholar]
  3. Berrevoets C. A., Doesburg P., Steketee K., Trapman J., Brinkmann A. O. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol Endocrinol. 1998 Aug;12(8):1172–1183. doi: 10.1210/mend.12.8.0153. [DOI] [PubMed] [Google Scholar]
  4. Brinkmann A. O., Blok L. J., de Ruiter P. E., Doesburg P., Steketee K., Berrevoets C. A., Trapman J. Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):307–313. doi: 10.1016/s0960-0760(99)00049-7. [DOI] [PubMed] [Google Scholar]
  5. Brinkmann A. O., Faber P. W., van Rooij H. C., Kuiper G. G., Ris C., Klaassen P., van der Korput J. A., Voorhorst M. M., van Laar J. H., Mulder E. The human androgen receptor: domain structure, genomic organization and regulation of expression. J Steroid Biochem. 1989;34(1-6):307–310. doi: 10.1016/0022-4731(89)90098-8. [DOI] [PubMed] [Google Scholar]
  6. Cadepond F., Ulmann A., Baulieu E. E. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med. 1997;48:129–156. doi: 10.1146/annurev.med.48.1.129. [DOI] [PubMed] [Google Scholar]
  7. Chang Ching-Yi, McDonnell Donald P. Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol Endocrinol. 2002 Apr;16(4):647–660. doi: 10.1210/mend.16.4.0818. [DOI] [PubMed] [Google Scholar]
  8. Cheng Shinta, Brzostek Sabrina, Lee Suzanne R., Hollenberg Anthony N., Balk Steven P. Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol. 2002 Jul;16(7):1492–1501. doi: 10.1210/mend.16.7.0870. [DOI] [PubMed] [Google Scholar]
  9. Dotzlaw Helmut, Moehren Udo, Mink Sigrun, Cato Andrew C. B., Iñiguez Lluhí Jorge A., Baniahmad Aria. The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol. 2002 Apr;16(4):661–673. doi: 10.1210/mend.16.4.0798. [DOI] [PubMed] [Google Scholar]
  10. Ghosh Jagadish C., Yang Xiaofang, Zhang Aihua, Lambert Millard H., Li Hui, Xu H. Eric, Chen J. Don. Interactions that determine the assembly of a retinoid X receptor/corepressor complex. Proc Natl Acad Sci U S A. 2002 Apr 23;99(9):5842–5847. doi: 10.1073/pnas.092043399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gregory C. W., He B., Johnson R. T., Ford O. H., Mohler J. L., French F. S., Wilson E. M. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001 Jun 1;61(11):4315–4319. [PubMed] [Google Scholar]
  12. Heinlein Cynthia A., Chang Chawnshang. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol. 2002 Oct;16(10):2181–2187. doi: 10.1210/me.2002-0070. [DOI] [PubMed] [Google Scholar]
  13. Heinzel T., Lavinsky R. M., Mullen T. M., Söderstrom M., Laherty C. D., Torchia J., Yang W. M., Brard G., Ngo S. D., Davie J. R. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature. 1997 May 1;387(6628):43–48. doi: 10.1038/387043a0. [DOI] [PubMed] [Google Scholar]
  14. Hermanson Ola, Glass Christopher K., Rosenfeld Michael G. Nuclear receptor coregulators: multiple modes of modification. Trends Endocrinol Metab. 2002 Mar;13(2):55–60. doi: 10.1016/s1043-2760(01)00527-6. [DOI] [PubMed] [Google Scholar]
  15. Horwitz K. B. The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev. 1992 May;13(2):146–163. doi: 10.1210/edrv-13-2-146. [DOI] [PubMed] [Google Scholar]
  16. Huang E. Y., Zhang J., Miska E. A., Guenther M. G., Kouzarides T., Lazar M. A. Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev. 2000 Jan 1;14(1):45–54. [PMC free article] [PubMed] [Google Scholar]
  17. Hörlein A. J., När A. M., Heinzel T., Torchia J., Gloss B., Kurokawa R., Ryan A., Kamei Y., Söderström M., Glass C. K. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature. 1995 Oct 5;377(6548):397–404. doi: 10.1038/377397a0. [DOI] [PubMed] [Google Scholar]
  18. Jackson T. A., Richer J. K., Bain D. L., Takimoto G. S., Tung L., Horwitz K. B. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol. 1997 Jun;11(6):693–705. doi: 10.1210/mend.11.6.0004. [DOI] [PubMed] [Google Scholar]
  19. Jepsen K., Hermanson O., Onami T. M., Gleiberman A. S., Lunyak V., McEvilly R. J., Kurokawa R., Kumar V., Liu F., Seto E. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell. 2000 Sep 15;102(6):753–763. doi: 10.1016/s0092-8674(00)00064-7. [DOI] [PubMed] [Google Scholar]
  20. Keller E. T., Ershler W. B., Chang C. The androgen receptor: a mediator of diverse responses. Front Biosci. 1996 Mar 1;1:d59–d71. doi: 10.2741/a116. [DOI] [PubMed] [Google Scholar]
  21. Kuil C. W., Berrevoets C. A., Mulder E. Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. J Biol Chem. 1995 Nov 17;270(46):27569–27576. doi: 10.1074/jbc.270.46.27569. [DOI] [PubMed] [Google Scholar]
  22. Kuiper G. G., de Ruiter P. E., Trapman J., Boersma W. J., Grootegoed J. A., Brinkmann A. O. Localization and hormonal stimulation of phosphorylation sites in the LNCaP-cell androgen receptor. Biochem J. 1993 Apr 1;291(Pt 1):95–101. doi: 10.1042/bj2910095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Liao Guoqing, Chen Liuh-Yow, Zhang Aihua, Godavarthy Aparna, Xia Fang, Ghosh Jagadish Chandra, Li Hui, Chen J. Don. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem. 2002 Nov 18;278(7):5052–5061. doi: 10.1074/jbc.M206374200. [DOI] [PubMed] [Google Scholar]
  24. Liu Zheng, Auboeuf Didier, Wong Jiemin, Chen J. Don, Tsai Sophia Y., Tsai Ming-Jer, O'Malley Bert W. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc Natl Acad Sci U S A. 2002 Jun 4;99(12):7940–7944. doi: 10.1073/pnas.122225699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Masiello David, Cheng Shinta, Bubley Glenn J., Lu Michael L., Balk Steven P. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem. 2002 May 15;277(29):26321–26326. doi: 10.1074/jbc.M203310200. [DOI] [PubMed] [Google Scholar]
  26. Nagy L., Kao H. Y., Chakravarti D., Lin R. J., Hassig C. A., Ayer D. E., Schreiber S. L., Evans R. M. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell. 1997 May 2;89(3):373–380. doi: 10.1016/s0092-8674(00)80218-4. [DOI] [PubMed] [Google Scholar]
  27. Nagy L., Kao H. Y., Love J. D., Li C., Banayo E., Gooch J. T., Krishna V., Chatterjee K., Evans R. M., Schwabe J. W. Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev. 1999 Dec 15;13(24):3209–3216. doi: 10.1101/gad.13.24.3209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Perissi V., Staszewski L. M., McInerney E. M., Kurokawa R., Krones A., Rose D. W., Lambert M. H., Milburn M. V., Glass C. K., Rosenfeld M. G. Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev. 1999 Dec 15;13(24):3198–3208. doi: 10.1101/gad.13.24.3198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Quigley C. A., De Bellis A., Marschke K. B., el-Awady M. K., Wilson E. M., French F. S. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev. 1995 Jun;16(3):271–321. doi: 10.1210/edrv-16-3-271. [DOI] [PubMed] [Google Scholar]
  30. Reid P., Kantoff P., Oh W. Antiandrogens in prostate cancer. Invest New Drugs. 1999;17(3):271–284. doi: 10.1023/a:1006344807086. [DOI] [PubMed] [Google Scholar]
  31. Robyr D., Wolffe A. P., Wahli W. Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol Endocrinol. 2000 Mar;14(3):329–347. doi: 10.1210/mend.14.3.0411. [DOI] [PubMed] [Google Scholar]
  32. Sack J. S., Kish K. F., Wang C., Attar R. M., Kiefer S. E., An Y., Wu G. Y., Scheffler J. E., Salvati M. E., Krystek S. R., Jr Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4904–4909. doi: 10.1073/pnas.081565498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Shang Yongfeng, Myers Molly, Brown Myles. Formation of the androgen receptor transcription complex. Mol Cell. 2002 Mar;9(3):601–610. doi: 10.1016/s1097-2765(02)00471-9. [DOI] [PubMed] [Google Scholar]
  34. Shi Xu-Bao, Ma Ai-Hong, Xia Liang, Kung Hsing-Jien, de Vere White Ralph W. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res. 2002 Mar 1;62(5):1496–1502. [PubMed] [Google Scholar]
  35. Smith C. L., Nawaz Z., O'Malley B. W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol. 1997 Jun;11(6):657–666. doi: 10.1210/mend.11.6.0009. [DOI] [PubMed] [Google Scholar]
  36. Steketee Karine, Timmerman Leon, Ziel-van der Made Angelique C. J., Doesburg Paul, Brinkmann Albert O., Trapman Jan. Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer. 2002 Jul 20;100(3):309–317. doi: 10.1002/ijc.10495. [DOI] [PubMed] [Google Scholar]
  37. Suzuki H., Akakura K., Komiya A., Aida S., Akimoto S., Shimazaki J. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate. 1996 Sep;29(3):153–158. doi: 10.1002/1097-0045(199609)29:3<153::aid-pros2990290303>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  38. Taplin M. E., Bubley G. J., Ko Y. J., Small E. J., Upton M., Rajeshkumar B., Balk S. P. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 1999 Jun 1;59(11):2511–2515. [PubMed] [Google Scholar]
  39. Veldscholte J., Berrevoets C. A., Brinkmann A. O., Grootegoed J. A., Mulder E. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry. 1992 Mar 3;31(8):2393–2399. doi: 10.1021/bi00123a026. [DOI] [PubMed] [Google Scholar]
  40. Veldscholte J., Ris-Stalpers C., Kuiper G. G., Jenster G., Berrevoets C., Claassen E., van Rooij H. C., Trapman J., Brinkmann A. O., Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 1990 Dec 14;173(2):534–540. doi: 10.1016/s0006-291x(05)80067-1. [DOI] [PubMed] [Google Scholar]
  41. Zegers N. D., Claassen E., Neelen C., Mulder E., van Laar J. H., Voorhorst M. M., Berrevoets C. A., Brinkmann A. O., van der Kwast T. H., Ruizeveld de Winter J. A. Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy. Biochim Biophys Acta. 1991 Jan 23;1073(1):23–32. doi: 10.1016/0304-4165(91)90178-j. [DOI] [PubMed] [Google Scholar]
  42. Zhang X., Jeyakumar M., Petukhov S., Bagchi M. K. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol Endocrinol. 1998 Apr;12(4):513–524. doi: 10.1210/mend.12.4.0089. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES